When.com Web Search

  1. Ads

    related to: reclast infusion pros and cons

Search results

  1. Results From The WOW.Com Content Network
  2. Does Medicare Cover Reclast Infusion? - AOL

    www.aol.com/does-medicare-cover-reclast-infusion...

    An older study from 2008 found that a 5-mg annual infusion of Reclast cost about $1,250 out-of-pocket. That said, the price can vary depending on the dispensing pharmacy.

  3. Zoledronic acid - Wikipedia

    en.wikipedia.org/wiki/Zoledronic_acid

    These include osteoporosis, high blood calcium due to cancer, bone breakdown due to cancer, Paget's disease of bone [3] and Duchenne muscular dystrophy (DMD). It is given by injection into a vein. [3] Common side effects include fever, joint pain, high blood pressure, diarrhea, and feeling tired. [3]

  4. Medication-related osteonecrosis of the jaw - Wikipedia

    en.wikipedia.org/wiki/Medication-related_osteo...

    Patients being treated for osteoporosis or non-malignant bone disease with oral bisphosphonates/quarterly or yearly infusions of intravenous bisphosphonates for >5 years; Patients being treated for osteoporosis or non-malignant bone disease with bisphosphonates/denosumab for any length of time as well as being treated with systemic glucocorticoids

  5. Discovery and development of bisphosphonates - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    They are used for the treatment of osteoporosis and other bone disorders that cause bone fragility and diseases where bone resorption is excessive. Osteoporosis is common in post-menopausal women and patients in corticosteroid treatment where biphosphonates have been proven a valuable treatment and also used successfully against Paget's disease ...

  6. Bisphosphonate - Wikipedia

    en.wikipedia.org/wiki/Bisphosphonate

    In large studies, women taking bisphosphonates for osteoporosis have had unusual fractures ("bisphosphonate fractures") in the femur (thigh bone) in the shaft (diaphysis or sub-trochanteric region) of the bone, rather than at the femoral neck, which is the most common site of fracture. However, these fractures are rare (12 in 14,195 women ...

  7. Denosumab - Wikipedia

    en.wikipedia.org/wiki/Denosumab

    In June 2010, denosumab was approved by the FDA for use in postmenopausal women with risk of osteoporosis [31] under the brand name Prolia, [32] and in November 2010, as Xgeva for the prevention of skeleton-related events in people with bone metastases from solid tumors. [33] Denosumab is the first RANKL inhibitor to be approved by the FDA. [31]

  1. Ad

    related to: reclast infusion pros and cons